RRC ID 56276
著者 Lyskova P, Hubka V, Svobodova L, Barrs V, Dhand NK, Yaguchi T, Matsuzawa T, Horie Y, Kolarik M, Dobias R, Hamal P.
タイトル Antifungal Susceptibility of the Aspergillus viridinutans Complex: Comparison of Two In Vitro Methods.
ジャーナル Antimicrob Agents Chemother
Abstract Cryptic species of Aspergillus fumigatus, including the Aspergillus viridinutans species complex, are increasingly reported to be causes of invasive aspergillosis. Their identification is clinically relevant, as these species frequently have intrinsic resistance to common antifungals. We evaluated the susceptibilities of 90 environmental and clinical isolates from the A. viridinutans species complex, identified by DNA sequencing of the calmodulin gene, to seven antifungals (voriconazole, posaconazole, itraconazole, amphotericin B, anidulafungin, micafungin, and caspofungin) using the reference European Committee on Antimicrobial Susceptibility Testing (EUCAST) method. The majority of species demonstrated elevated MICs of voriconazole (geometric mean [GM] MIC, 4.46 mg/liter) and itraconazole (GM MIC, 9.85 mg/liter) and had variable susceptibility to amphotericin B (GM MIC, 2.5 mg/liter). Overall, the MICs of posaconazole and the minimum effective concentrations of echinocandins were low. The results obtained by the EUCAST method were compared with the results obtained with Sensititre YeastOne (YO) panels. Overall, there was 67% agreement (95% confidence interval [CI], 62 to 72%) between the results obtained by the EUCAST method and those obtained with YO panels when the results were read at 48 h and 82% agreement (95% CI, 78 to 86%) when the results were read at 72 h. There was a significant difference in agreement between antifungals; agreement was high for amphotericin B, voriconazole, and posaconazole (70 to 86% at 48 h and 88 to 93% at 72 h) but was very low for itraconazole (37% at 48 h and 57% at 72 h). The agreement was also variable between species, with the maximum agreement being observed for A. felis isolates (85 and 93% at 48 and 72 h, respectively). Elevated MICs of voriconazole and itraconazole were cross-correlated, but there was no correlation between the other azoles tested.
巻・号 62(4)
公開日 2018-4-1
DOI 10.1128/AAC.01927-17
PII AAC.01927-17
PMID 29437620
PMC PMC5913995
MeSH Amphotericin B / pharmacology Antifungal Agents / pharmacology* Aspergillus / drug effects* Echinocandins / pharmacology Itraconazole / pharmacology Microbial Sensitivity Tests Triazoles / pharmacology Voriconazole / pharmacology
IF 4.715
引用数 4
リソース情報
病原真核微生物 病原真菌:IFM 57291T (= CCF 4670T), IFM 57290 (= CCF 4666), IFM 61334T (= JCM 19878T), IFM 61333 (= CCF 4899), IFM 61337 (= JCM 19879), IFM 61338( = JCM 19880), IFM 61339 (= CCF 4903), IFM 61340 (= CCF 4904), IFM 61345 (= CCF 5633), IFM 61346 (= CCF 4906), IFM 61349 (= CCF 4907), IFM 61362 (= CCF 4908), IFM 59922 (= CCF 4560), IFM 59923 (= CCF 4569), IFM 53589T (= CBS 105.55T), IFM 46584 (= CCF 4645), IFM 59564 (= CCF 5612), IFM 60053 (= CCF 4559), IFM 54303 (= CCF 4570), IFM 55266 (= CCF 5644), IFM 57289 (= CCF 4665), IFM 59502 (= CCF 4561), IFM 59793 T (= KUFC 6349 T), IFM 61157 (= KUFC 6397), IFM 46972 T (= CBS 114218 T), IFM 46973 T (= CBS 114217 T), IFM 5058 (= CCF 4662), IFM 51744 (= CCF 4671), IFM 53868 (= CCF 4667), IFM 54131 (= CCF 4663), IFM 54132 (= CCF 4664), IFM 54745 (= CCF 4661), IFM 55207 (= NBRC 31952), IFM 62155 (= CCF 4668), IFM 47045T (= IMI 367415T)